Olodaterol/tiotropium bromide

Drug Profile

Olodaterol/tiotropium bromide

Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva Respimat

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Dec 2016 Boehringer Ingelheim plans a clinical trial for Chronic obstructive pulmonary disease in Italy (NCT03003494)
  • 21 Dec 2016 Chemical structure information added
  • 17 Nov 2016 Boehringer Ingelheim plans a phase I trial for Chronic obstructive pulmonary disease in China (Inhalation) (NCT02969317)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top